# Safety and efficacy of nivolumab in combination with S-1/capecitabine plus oxaliplatin in patients with previously untreated, unresectable, advanced, or recurrent gastric/gastroesophageal junction cancer: interim results of a randomized, phase II trial (ATTRACTION-4)

**Type:** Papers  
**Canonical URL:** https://scholariq.org/papers/safety-and-efficacy-of-nivolumab-in-combination-with-s-1-capecitabine-plus/

## Facts

| Field | Value |
| --- | --- |
| Author Names | Narikazu Boku,Min‐Hee Ryu,Ken Kato,Hyun Cheol Chung,Keiko Minashi,K.-W. Lee,H. Cho,Won Ki Kang,Yoshito Komatsu,Masahiro Tsuda,Kensei Yamaguchi,Hiroki Hara,Soichi Fumita,Mizutomo Azuma,L.-T. Chen,Yoon‐Koo Kang |
| Citations | 325 |
| DOI | 10.1093/annonc/mdy540 |
| Fields | Medicine |
| Open Access | true |
| OA Status | bronze |
| OA URL | http://www.annalsofoncology.org/article/S0923753419310361/pdf |
| OpenAlex ID | https://openalex.org/W2906436263 |
| PMID | 30566590 |
| Type | article |
| Year | 2018 |

## Paper authors

- [Soichi Fumita](https://scholariq.org/researchers/soichi-fumita/)

## Paper journal

- [Annals of Oncology](https://scholariq.org/journals/annals-of-oncology/)

## Paper primary topic

- [Gastric Cancer Management and Outcomes](https://scholariq.org/topics/gastric-cancer-management-and-outcomes/)

## Paper topics

- [Gastric Cancer Management and Outcomes](https://scholariq.org/topics/gastric-cancer-management-and-outcomes/)
- [Esophageal Cancer Research and Treatment](https://scholariq.org/topics/esophageal-cancer-research-and-treatment/)
- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.